Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
22.82B
Market cap22.82B
Price-Earnings ratio
16.50
Price-Earnings ratio16.50
Dividend yield
Dividend yield
Average volume
1.70M
Average volume1.70M
High today
High today
Low today
Low today
Open price
$115.97
Open price$115.97
Volume
0.00
Volume0.00
52 Week high
$118.97
52 Week high$118.97
52 Week low
$67.17
52 Week low$67.17

Stock Snapshot

As of today, Incyte(INCY) shares are valued at $114.43. The company's market cap stands at 22.82B, with a P/E ratio of 16.50.

On 2026-07-14, Incyte(INCY) shares started trading at $115.97, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 1.7M.

The stock's 52-week range extends from a low of $67.17 to a high of $118.97.

The stock's 52-week range extends from a low of $67.17 to a high of $118.97.

INCY News

TipRanks 1h
Incyte: VGA039 Data Reinforces Diversification Strategy as Analyst Reiterates Hold and Keeps $103 Price Target Unchanged

Analyst Judah Frommer from Morgan Stanley maintained a Hold rating on Incyte and keeping the price target at $103.00. TipRanks Welcomes a New ETF – NYSE:RANK Ti...

TipRanks 2h
Incyte price target raised to $134 from $117 at Barclays

Barclays raised the firm’s price target on Incyte (INCY) to $134 from $117 and keeps an Overweight rating on the shares. The firm adjusted the price target as p...

MarketWatch 15h
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch

...

Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch

Analyst ratings

55%

of 29 ratings
Buy
41.4%
Hold
55.2%
Sell
3.4%

More INCY News

Benzinga 23h
Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder

VWD is the most common inherited bleeding disorder, affecting about 1% of the population. It is caused by a deficiency or malfunction of the von Willebrand fac...

Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder
TipRanks 1d
Incyte announces safety, efficacy data from VGA039 study

Incyte (INCY) announced complete safety and efficacy data from all patients enrolled in the Phase 1/2 multidose study of VGA039, a Protein S-targeting, investig...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.